title: [Value of nerve growth factor levels in overactive bladder syndrome: alterations after botulinum toxin therapy].
abstract: OBJECTIVE
  Several studies discussing the pathology of overactive bladder suggested changes in urinary proteins. The neurotrophin "nerve growth factor" (NGF) seems to be an important marker in overactive bladder syndrome (OAB). In this prospectively designed study we evaluated NGF blood levels (sNGF) initially and after injection of botulinum toxin type A (BTX-A) in the detrusor muscle in patients suffering from idiopathic OAB.
  
  
  METHODS
  Blood samples were obtained from 26 patients (66.5 years, 28-83) with idiopathic OAB. sNGF levels were measured before and 4 weeks after BTX-A treatment by enzyme-linked immunosorbent assay (ELISA). A group of 32 healthy persons with normal bladder function served as controls (41 years, 19-60). sNGF was evaluated in relation to clinical data and the severity of OAB (wet/dry).
  
  
  RESULTS
  Significantly higher sNGF levels were detected in patients with OAB compared to the control group (58.8 vs 2.0 pg/ml, p<0.005). Further, sNGF levels were elevated in patients with wet OAB compared to patients with dry OAB (85.0 vs 0.73 pg/ml, p<0.005). Patients > 60 years showed significantly higher sNGF levels (77.2 vs 8.9 pg/ml, p<0.05) compared to younger OAB patients. After BTX-A therapy sNGF levels decreased significantly compared to baseline (p<0.005).
  
  
  CONCLUSIONS
  NGF appears to play a decisive role in OAB. Its use as a biomarker in both the diagnostics and follow-up after therapy seems promising. To what extent sNGF can be useful as a biomarker or in therapy monitoring needs to be examined prospectively in a larger population.
authors: Klinik für Urologie und Kinderurologie, Universitätsklinikum Gießen und Marburg GmbH - Standort Marburg, Baldingerstraße, 35043 Marburg, Deutschland.
authors: S
authors: S
authors: Knippschild
authors: C
authors: C
authors: Frohme
authors: P
authors: P
authors: Olbert
authors: R
authors: R
authors: Hofmann
authors: A
authors: A
authors: Hegele
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020932:Nerve Growth Factor / Q000097:blood*; D017060:Patient Satisfaction; D011446:Prospective Studies; D012016:Reference Values; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology*; D014563:Urodynamics / Q000187:drug effects / Q000502:physiology; D055815:Young Adult
chemical_list: D020932:Nerve Growth Factor; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA